calltech-consultant.com

Innovation: Intelligent bacteria demonstrate high efficacy in the treatment of widespread disease irritable bowel syndrome with typical symptoms of recurrent diarrhoea, abdominal pain, bloating and constipation

4.5 (666) · € 17.50 · En stock

New therapy with unique bacterial strain B. bifidum HI-MIMBb75 promises help for approximately 80 million Europeans suffering from irritable bowel syndrome1 World's largest clinical OTC irritable bowel syndrome trial investigating the efficacy of this particular strain published in the renowned medical journal The Lancet Gastroenterology & Hepatology2 Results show significant efficacy for all predominant irritable bowel syndrome symptoms and all subtypes while simultaneously improving patients’ quality of life2 (Gräfelfing/Munich, Germany) The world's largest OTC irritable bowel syndrome (IBS) trial comes up with remarkable results, which were recently published in the renowned medical journal The Lancet Gastroenterology & Hepatology. For the first time, leading German scientists around Prof. Dr. Peter Layer (Israelitic Hospital Hamburg) were able to prove the significant efficacy of a heat-inactivated bacterial strain on patients with IBS. Trial results show that B. bifidum HI-MIMBb75

PDF) Irritable bowel syndrome: contemporary nutrition management strategies

Gastrointestinal Disorders, Free Full-Text

(PDF) Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults

Irritable bowel syndrome diagnosis and management: A simplified algorithm for clinical practice - Paul Moayyedi, Fermín Mearin, Fernando Azpiroz, Viola Andresen, Giovanni Barbara, Maura Corsetti, Anton Emmanuel, A Pali S Hungin, Peter

Gastroenterology Today Autumn 2016 by Media Publishing Company - Issuu

Pathogens, Free Full-Text

Irritable bowel syndrome - The Lancet

The neurobiology of irritable bowel syndrome

Clinical Trials and Studies - IFFGD

Irritable bowel syndrome: a gut microbiota-related disorder? American Journal of Physiology-Gastrointestinal and Liver Physiology

Frontiers Current Treatment Options and Therapeutic Insights for Gastrointestinal Dysmotility and Functional Gastrointestinal Disorders

Frontiers The Microbiome and Irritable Bowel Syndrome – A Review on the Pathophysiology, Current Research and Future Therapy

Cureus, Effectiveness of Rifaximin on the Outcomes of Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Irritable bowel syndrome Nature Reviews Disease Primers

Pharmaceuticals, Free Full-Text